



## Ennaid Therapeutics Patent Portfolio

### Branch of Coronavirus Drug Development (CoVDD)

#### 1. ENUZZZ

USPTO Application number: 63/120,633

Filing Date: December 2, 2020

**“CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS”**

**Exclusively licensed worldwide by Ennaid Therapeutics**

Inventors: Ram Samudrala, Zackary Falls and William Mangione

Filed by: Ennaid Therapeutics

Impact: Relates to viral inhibition and antiviral treatment methods especially for corona virus treatment in humans and animals

#### 2. ENUYYY

USPTO Application number: 63/116,669

Filing Date: November 20, 2020

**“METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION”**

**Exclusively licensed worldwide by Ennaid Therapeutics**

Inventors: Horacio Emilio Pérez-Sánchez, José Pedro Cerón-Carrasco, Jorge de la Peña García, Alfonso Pérez-Garrido and Antonio Jesús Banegas Luna

Filed by: Ennaid Therapeutics

Covers the latest scientific evidence for Ennaid’s COVID-19 therapeutic

#### 3. ENU300 & ENU400

USPTO Application number: 63/081,464

Filing Date: September 22, 2020

**“METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION”**

ENU300 and ENU400 are repurposed drugs used to treat COVID-19.

**Exclusively licensed worldwide by Ennaid Therapeutics**

Inventors: Horacio Emilio Pérez-Sánchez, José Pedro Cerón-Carrasco, Jorge de la Peña García, Alfonso Pérez-Garrido and Antonio Jesús Banegas Luna

Filed by: Ennaid Therapeutics

Covers the latest scientific evidence for Ennaid’s COVID-19 therapeutic

#### 4. ENUXXX

USPTO Application number: 63/056,867

Filing Date: July 27, 2020

**“METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION”**

**Exclusively licensed worldwide by Ennaid Therapeutics**

Inventors: Horacio Emilio Pérez-Sánchez, José Pedro Cerón-Carrasco, Jorge de la Peña García, Alfonso Pérez-Garrido and Antonio Jesús Banegas Luna

Filed by: Ennaid Therapeutics

Relates to viral inhibition and antiviral treatment methods especially for corona virus treatment in humans and animals

### Branch of Infectious Diseases Drug Development (IDDD)

#### 5. EtxR12

USPTO Application number: 15/369,893

Published Patent #: US20180155398A1, WO2018106418A1

**“FLAVIVIRUS BINDING, ENTRY-OBSTRUCTING, PROTEASE-RESISTANT PEPTIDE”**

Broadly covers all flaviviruses, allows for broad-spectrum drug development and oral administration of antiviral peptides

**Exclusively owned by Ennaid Therapeutics**

**Filed by: Ennaid Therapeutics**

**Patent was issued by the USPTO on April 24, 2020**

**Is also in examination queue in India for issuance**

This invention relates to inhibition of viruses by preventing fusion of the virus to healthy cells' protein envelope. This is targeted to viruses such as Dengue and Zika and is extraordinarily suitable for oral administration as well as other delivery methods.

#### 6. DN81

USPTO Application number: 12/668,828

Published Patent #: US8541377B2, WO2009045596A2

Expiration: 2/21/2030

**“OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE”**

**Exclusively licensed worldwide by Ennaid Therapeutics for the life of the patent**

#### 7. 10AN

USPTO Application number:

Published Patent #: US8637472B2

Expiration: 12/7/2029

**“OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE”**

**Exclusively licensed worldwide by Ennaid Therapeutics for the life of the patent**

## Branch of Digital Health (EDH)

### 8. iClickCare®

Ennaid has a software service, **iClickCare®**, for in-home, HIPAA secure, app/web based clinical trial data entry to immediately conduct COVID-19 and other coronavirus clinical trials. The software is available for inclusion into electronic medical records. Ennaid may later utilize the software for telemedicine with the application, **Hybrid Store-and-Forward®**. ClickCare® offers many solutions to broadly advance Ennaid's drug development initiatives and its digital health platform. **Ennaid's iClickCare®** has patents-pending.

### 9. ROME

Ennaid has an algorithm-based digital health diagnostics product, **ROME (Repeatable Objective Measure of Eyetrack)**, that can diagnose, objectively and repeatedly measure traumatic brain injuries over time (neurological disorders such as, concussions, Parkinson's, Alzheimer's, etc...).

## Branch of Oncology Drug Development (ODD)

### 10. COLORECTAL CANCER DRUG

European Patent Application number: EP18382696

**"IMIPRAMINE FOR USE AS INHIBITOR OF FASCIN1 OVEREXPRESSION"**

Filed by: Fundacion Universitaria San Antonio

**Exclusively licensed worldwide by Ennaid Therapeutics for the life of the patent**

The invention pertains to a **repurposed drug** that treats advanced colorectal cancer.

## Branch of Medical Mobile Units (MMU)

The branch consists of numerous components that provide the flexibility to deploy an entire hospital or deploy a small laboratory. The hospital deployment consists of units that provide patient beds, clinical support, lab support, crew quarters, kitchen and other resources.

Units are equipped with the necessary hospital medical equipment needed to perform vital patient care. Equipment includes, but is not limited to, defibrillators, patient monitors, ventilators and infusion pumps. All laboratory and medical units would ideally be Biosafety Level 3 (BSL3) certified and will comply with all SafeBridge classifications for drug handling to ensure occupational health safety.

The equipment consists of a mix of self-contained tractor trailer units and straight trucks. Tractor trailer units are used to provide maximum space while reducing delays in deployment due to

mechanical issues with the truck. The straight truck units are designed to access locations that are not accessible to larger units.

Each unit is designed to be powered with either shore power or with the on-board generator. In the case of a hospital deployment, it is preferable to include larger units to provide power to the entire operation as well as increased storage capacity for fuel, water, sewage and supplies. All inhabited units include heating and cooling and HEPA filtered airflow. All medical spaces are designed to meet the guidelines for World Health Organization BSL3.